Chinese biotech firm WuXi AppTec Co. has been one of the market’s hottest stocks this year, but its rally is starting to attract a growing group of skeptics. Short positions relative to free float ...

WASHINGTON, Aug 7 (Reuters) - A U.S. judge on Friday barred the Defense Department from including Chinese biotechnology company WuXi ‌AppTec Co on a list of companies believed to support Beijing's ...

WORCESTER – After a snag in 2024, the construction of WuXi Biologics has resumed. The company is aiming to complete its Worcester location in 2028, said a spokesperson for the Chinese pharmaceutical ...

Critical Central Massachusetts business news updated daily. Immediate access to all subscriber-only content on our website. Bi-weekly print or digital editions of our award-winning publication.

June 11 (Reuters) - A Chinese biotechnology company sued the U.S. government on Thursday over being placed on a list of businesses from ‌China that the U.S. Department of Defense has linked to that ...

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing ...

SHANGHAI, March 23, 2026 /PRNewswire/ --WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today ...

For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and pharmaceutical companies, operated under cloud, as Congress threatened to restrict its ...

WuXi Biologic's facility in Worcester, seen here in December. Progress at the site has been slow, as the China-based firm has sold off some of its international assets. PHOTO ERIC CASEY CORRECTION: ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min WuXi STA expects to hire about ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

CDMO WuXi Biologics signed a deal with Candid Therapeutics, a clinical-stage biotechnology company, giving Candid exclusive global rights to a preclinical trispecific T-cell engager discovered on WuXi ...